Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11857630 | 0.85 | PTGDR2 (0.74) | MEN1KMT2APTGDR2MAPT | |
| SCHEMBL5544242 | 0.84 | PTGDR2 (0.76) | MEN1KMT2APTGDR2LMNAMAPT | |
| SCHEMBL8292005 | 0.83 | PTGDR2 (0.74) | MEN1KMT2APTGDR2LMNAMAPT | |
| SCHEMBL5820072 | 0.83 | PTGDR2 (1.00) | MEN1KMT2APTGDR2LMNAMAPT | |
| SCHEMBL2818129 | 0.81 | PTGDR2 (1.00) | MEN1KMT2APTGDR2POLBALDH1A1 | |
| SCHEMBL1398615 | 0.80 | ALDH1A1 (0.62) | MEN1KMT2APTGDR2LMNAMAPT | |
| SCHEMBL5055133 | 0.79 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL2756231 | 0.77 | ALDH1A1 (0.59) | MEN1KMT2APTGDR2LMNAMAPT | |
| SCHEMBL19626502 | 0.77 | PTGDR2 (0.73) | MEN1KMT2APTGDR2LMNAMAPT | |
| SCHEMBL13116341 | 0.76 | PTGDR2 (0.80) | PTGDR2POLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| WO-2005037257-A2 | NOVEL ALANYL-AMINO PEPTIDASE INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | DNPEP, PREP, ANPEP | MEN1 2581/4885KMT2A 3390/4885PTGDR2 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.